187 Hospital of PLA
187 Hospital of PLA
Zhu Q.-C.,187 Hospital of PLA |
Wang Y.-H.,187 Hospital of PLA |
Yu S.-Y.,187 Hospital of PLA
Cancer Research and Clinic | Year: 2013
Objective: To investigate the effect of argatroban on C-reactive protein (CRP) and therapeutic efficacy in patients of malignant tumor complicated by acute lower limbs deep venous thrombosis (DVT). Methods 56 patients of malignant tumor complicated by acute lower limbs DVT were randomly divided into two groups. In observation group (n = 28), argatroban was given intravenously as anticoagulation. Urokinase as thrombolysis and warfarin as anticoagulation were used in the control group (n = 28). The concentrations of serum CRP were detected before treatment and on the 14th day of post-treatment in observation group and control group. Recanalization and therapeutic effect of DVT were compared. Results: Before treatment, there was no significant differences in the serum CRP concentrations between observation group and control group [(46.44±28.82) mg/L vs (45.96±29.40) mg/L, F = 0.004, P = 0.951]. On the 14th day of post-treatment, the CRP concentrations in observation group and control group were lower than those of pretreatment (F = 25.996, P < 0.05, F = 4.828, P < 0.05). Compared with the 14th day of post-treatment, the CRP concentration of observation group was lower than that of control group [(16.97±10.22) mg/L vs (31.63±18.07) mg/L, F = 13.965, P < 0.01]. Recanalization rate of observation group on the 14th day of post-treatment (96.43%, 27/28) was higher than that in control group (67.86%, 19/28) (x2 = 8.204, P = 0.017). Therapeutic effect rate of observation group on the 14th day of post-treatment (96.43%, 27/28) was higher than that in control group (75.00%, 21/28) (x2 = 6.205, P = 0.045). Conclusion Argatroban can decrease serum level of CRP in patient of malignant tumor complicated by acute lower limbs DVT, which is favorable for improvement of clinical effectiveness.
Shen H.,187 Hospital of PLA |
Tu R.,187 Hospital of PLA |
Li W.,187 Hospital of PLA |
He G.,187 Hospital of PLA |
And 4 more authors.
Iranian Red Crescent Medical Journal | Year: 2016
Background: Renal cell carcinoma (RCC) is acommonmalignancy of the urinary system with high rates of morbidityandmortality. Objectives: This study aimed to investigate and analyze the clinical efficacy of retroperitoneal laparoscopic partial nephrectomy and laparoscopic radical nephrectomy for the treatment of small RCC. Methods: In this retrospective study of 45 patients with small RCC, the patients were divided into two treatment groups: Group A (retroperitoneal laparoscopic partial nephrectomy, 25 cases) and Group B (retroperitoneal laparoscopic radical nephrectomy, 20 cases). Results: There were no statistically significant differences in the operative time, amount of intraoperative blood loss, length of hospital stay, preoperative creatinine level, postoperative creatinine level after 24 hours, and survival rate after 1, 2, and 3 years between the two groups (P > 0.05). Conclusions: There were no significant differences in the survival rates and short-term postoperative complications between the laparoscopic partial nephrectomy group and the laparoscopic radical nephrectomy group for small RCC, but the former was slightly more effective. © 2016, Iranian Red Crescent Medical Journal.
Ma Y.-C.,Northwest University, China |
Ma Y.-C.,Chinese Academy of Sciences |
Zhang M.,Northwest University, China |
Zhang M.,Chinese Academy of Sciences |
And 4 more authors.
Zhongguo Zhongyao Zazhi | Year: 2014
The chemical constituents from cytotoxic fraction of the Callicarpa nudiflora extract were isolated and purified by a combination of HP-20 macroporous resin, silica gel and Sephadex LH-20 column chromatographies. The structures were elucidated on the basis of the spectroscopic data and comparison of their spectroscopic data with reported data. The cytotoxicity was evaluated by the MTT assay. The 50% and 70% EtOH elutions of EtOH-extract showed significant cytotoxic activities, leading to the isolation of twelve compounds, which were identified as luteoloside(1) , lutedin-4-O-β-D-glucoside(2) , 6-hydroxyluteolin-7-O-β-glucoside(3) , lutedin-7-O-neohesperidoside(4) , rhoifolin (5) , luteolin-7 , 4-di-O-glucoside (6) , forsythoside B(7), acteoside (8) , alyssonoside (9) , catalpol(10) , nudifloside(11) , and leonuride(12). Compounds 3-6, 10 and 12 were isolated from this genus for the first time, and compound 9 was isolated from this plant for the first time. The cytotoxicity assay demonstrated that flavonoids 1-6, in various concentrations, showed monolithic proliferation inhibitory activities against Heia, A549 and MCF-7 cell lines. Compounds 3, 5 and iridoid glycoside 11 possessed higher cytotoxicacivities. In short, flavonoids are the main components of cytotoxic extract from C. nudiflora, while phenylethanoid glycosides are the predominant ingredient but inactive to cancer cell lines. In addition, the minor iridoid glycoside expressed weak cytotoxic activity.
Zhu Q.,187 Hospital of PLA
Cancer Research and Clinic | Year: 2015
Objective: To investigate the expression of bone sialoprotein (BSP) in prostate cancer and its clinical significance. Methods: Prostate cancer tissues of different pathological grades (68 cases) and benign prostatic hyperplasia tissues (22 cases) were selected. SP method was used to detect the expression of BSP. Serum total prostate-specific antigen (tPSA) levels of prostate cancer were detected by electrochemiluminescence immunoassay before the operation. Results: Compared with no or low expression in the adjacent normal glandular tissues, the detectable levels of BSP were examined in most of the prostate cancer tissues. The expression rate of BSP in prostate cancer tissues was higher than that in benign prostatic hyperplasia tissues [76.47 % (52/68) vs 13.64 % (3/22), χ2 = 27.614, P < 0.001]. The expression rates of BSP in well differentiated, moderately differentiated and poorly differentiated tissues according to cell differentiating degree (Gleason system) were 75.0 % (12/16), 77.5 % (31/40) and 75.0 % (9/12) respectively. There was no significant difference in various pathological grading χ2 = 0.057, P = 0.972). The expression rates of BSP in pathological stage pT2, pT3 and pT4 tissues were 62.16 % (23/37), 95.24 % (20/21) and 90.0 % (9/10) respectively. A statistically significant association was found between BSP expression and pathological stage (χ2 = 9.338, P = 0.009). Serum tPSA level of prostate cancer group with BSP expression was higher than that with no BSP expression [(69.06±25.52) μg/L vs (38.00±21.64) μg/L, F= 19.355, P< 0.001]. Conclusion: The high expression of BSP in prostate cancer has a relationship with pathological stage and serum tPSA level, it may play an important role in the biological behaviour of prostate cancer.